|Articles|October 28, 2019
Shifting The Paradigm for Retinal Disease Management
Advertisement
Trouble viewing this PDF?
If you are unable to download this pdf file, please try again in another browser.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Increasing the knowledge base of GA is key to individualizing patient therapy
2
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved by FDA
3
REGENXBIO completes enrollment in ATMOSPHERE and ASCENT trials of sura-vec in wet AMD
4
Quantifying intermittent retinal capillary perfusion in RVO and PDR
5